王忠芳研究员
教育经历
1996.09-2001.07，山东大学公共卫生学院，卫生检验专业，学士
2001.08-2004.07，中国协和医科大学卫生部临床中心，临床检验专业，硕士
2006.10-2010.09，德国李比希-吉森大学医学病毒系，医学病毒学专业，博士
工作经历
2004.08-2006.09，中国协和医科大学，卫生部临床检验中心分子诊断与免疫室，助理研究员
2010.10-2012.04，比利时根特大学病毒系，博士后
2012.05-2014.05，墨尔本大学 微生物与免疫系，中澳交换学者
2014.05-2018.04，墨尔本大学微生物与免疫系，博士后
2018.04至今，广州医科大学 呼吸疾病国家重点实验室，教授
2022.10至今，广州国家实验室 药物与疫苗研究部，研究员
研究简介
王忠芳，教授，博士生导师。广州实验室 PI、检测评价中心主任，呼吸疾病全国重点实验室 PI。国家重大人才项目领军人才 (2023)、珠江学者(2019)。从事新/突发呼吸道病毒感染免疫及潜伏病毒(CMV、EBV) 感染免疫研究 16 年，先阐述了人高致病性禽流感(H7N9) 和新冠感染的T细胞免疫动力学及分子机制，描绘了新冠T细胞在新冠中特征和与中和抗体的关系，完善了病毒感染后T细胞应答的启动和分化的基础理论。先后主持国家自然基金面上项目 3 项，国家重点研发计划子课题 3 项，广东省基础与应用基础研究重点项目3 项，实验室专项项目3 项。先后在 Cell Discoy, SignaLransduct Target Ther, Am J Respir Crit Care Med, Nat Commun等期刊发表 SCI 论文 60 余篇，申请专利 2 项。在研经费 3995 万。
人才头衔与荣誉奖励
1. 国家重大人才项目领军人才获得者；
2. 珠江学者；
3. 人社部高层次留学人才；
4. 广州市高层次人才-优秀专家A证。
代表性成果
1.Wu JD, Li JX, Liu J, Wang HM, Zhou GH, Li J, Wu D, Chen X, Feng Y, Qi XY, Wang X, Gou JB, Ma TL, Yang XY, Xu LF, Wan P, Zhu T, Wang ZF, Zhu FC; CanSino COVID-19 Study Group. Safety, immunogenicity, and efficacy of the mRNA vaccine CS 2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial. Lancet Infect Dis. 2023 Sep;23(9):1020-1030. doi: 10.1016/S1473-3099(23)00199-8IF: 56.3 Q1 . Epub 2023 May 19. PMID: 37216958.
2.Wang J, Li K, Mei X, Cao J, Zhong J, Huang P, Luo Q, Li G, Wei R, Zhong N, Zhao Z, Wang Z. SARS-CoV-2 vaccination-infection pattern imprints and diversifies T cell differentiation and neutralizing response against Omicron subvariants. Cell Discov. 2022 Dec 21;8(1):136. doi: 10.1038/s41421-022-00501-3. PMID: 36543767; PMCID: PMC9769462.
3.Zhong J, Liu S, Cui T, Li J, Zhu F, Zhong N, Huang W, Zhao Z, Wang Z. Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants. Emerg Microbes Infect. 2022 Dec;11(1):2689-2697. doi: 10.1080/22221751.2022.2132881. PMID: 36197655; PMCID: PMC9639505.
4.Zhao Z, Cui T, Huang M, Liu S, Su X, Li G, Song T, Li W, Zhong N, Xu M, Yang X, Huang W,Wang Z. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants. Emerg Microbes Infect. 2022 Dec;11(1):829-840. doi: 10.1080/22221751.2022.2048969. PMID: 35230230; PMCID: PMC8928863.
5.Wang Z, Yang X, Mei X, Zhou Y, Tang Z, Li G, Zhong J, Yu M, Huang M, Su X, Lin B, Cao P, Yang J, Ran P. SARS-CoV-2-specific CD4+ T cells are associated with long-term persistence of neutralizing antibodies. Signal Transduct Target Ther. 2022 Apr 23;7(1):132. doi: 10.1038/s41392-022-00978-0. PMID: 35461307; PMCID: PMC9034077.
6.Wang Z, Yang X, Zhong J, Zhou Y, Tang Z, Zhou H, He J, Mei X, Tang Y, Lin B, Chen Z, McCluskey J, Yang J, Corbett AJ, Ran P. Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection. Nat Commun. 2021 Mar 19;12(1):1724. doi: 10.1038/s41467-021-22036-z. PMID: 33741972; PMCID: PMC7979809.
7.Wang Z, Yang X, Zhou Y, Sun J, Liu X, Zhang J, Mei X, Zhong J, Zhao J, Ran P. COVID-19 Severity Correlates with Weaker T-Cell Immunity, Hypercytokinemia, and Lung Epithelium Injury. Am J Respir Crit Care Med. 2020 Aug 15;202(4):606-610. doi: 10.1164/rccm.202005-1701LE. PMID: 32608999; PMCID: PMC7427397.
8.Wang Z, Zhu L, Nguyen THO, Wan Y, Sant S, Quiñones-Parra SM, Crawford JC, Eltahla AA, Rizzetto S, Bull RA, Qiu C, Koutsakos M, Clemens EB, Loh L, Chen T, Liu L, Cao P, Ren Y, Kedzierski L, Kotsimbos T, McCaw JM, La Gruta NL, Turner SJ, Cheng AC, Luciani F, Zhang X, Doherty PC, Thomas PG, Xu J, Kedzierska K. Clonally diverse CD38+HLA-DR+CD8+ T cells persist during fatal H7N9 disease. Nat Commun. 2018 Feb 26;9(1):824. doi: 10.1038/s41467-018-03243-7. PMID: 29483513; PMCID: PMC5827521.
9.Wang Z, Wan Y, Qiu C, Quiñones-Parra S, Zhu Z, Loh L, Tian D, Ren Y, Hu Y, Zhang X, Thomas PG, Inouye M, Doherty PC, Kedzierska K, Xu J. Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8⁺ T cells. Nat Commun. 2015 May 13;6:6833. doi: 10.1038/ncomms7833. PMID: 25967273; PMCID: PMC4479016.
10.Wang Z, Zhang A, Wan Y, Liu X, Qiu C, Xi X, Ren Y, Wang J, Dong Y, Bao M, Li L, Zhou M, Yuan S, Sun J, Zhu Z, Chen L, Li Q, Zhang Z, Zhang X, Lu S, Doherty PC, Kedzierska K, Xu J. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):769-74. doi: 10.1073/pnas.1321748111. Epub 2013 Dec 23. PMID: 24367104; PMCID: PMC3896201.